autologous anti-mesothelin T-cell receptor fusion construct/PD-1:CD28 switch receptor-expressing T cells TC-510
Term · Oncology and biomedicine · MLC-T-ONC-011476
A preparation of autologous T lymphocytes that have been genetically engineered to express a single-domain antibody that recognizes human tumor-associated antigen (TAA) mesothelin (MSLN), fused to the N-terminus of the CD3-epsilon T-cell receptor (TCR) subunit which, upon expression is incorporated into the endogenous TCR complex, and a PD-1:CD28 switch receptor composed of the extracellular ligand binding domain of the human inhibitory receptor programmed cell death protein 1 (PD-1; PDCD1) fused to the transmembrane and cytoplasmic co-stimulatory signaling domains of CD28, with potential immunomodulating and antineoplastic activities. Upon reintroduction into the patient, autologous anti-MSLN TCR fusion construct/PD-1:CD28 switch receptor-expressing T cells TC-510 specifically target and bind to MSLN-expressing tumor cells. This leads to T-cell activation and T-cell mediated lysis of MSLN-expressing tumor cells. The switch receptor expressed by the engineered T cells TC-510 targets and binds to the PD-1 ligands, programmed cell death ligand 1 (PD-L1) and 2 (PD-L2), expressed on tumor cells. The nature of the PD-1/CD28 switch receptor fusion protein prevents the normal PD1/PD-L1-mediated T-cell suppression and, instead, promotes signaling through the CD28 domain, which results in the stimulation of T-lymphocytes. This induces enhanced toxicity against tumor cells. Mesothelin, a cell surface glycoprotein involved in cell adhesion, is overexpressed in a variety of cancer cell types.
| Identifier | MLC-T-ONC-011476 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | autologous anti-MSLN TCR fusion construct/PD-1:CD28 switch receptor-expressing T cells TC-510; autologous anti-mesothelin PD-1:CD28 switch receptor-expressing TRuC-T cells TC-510 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-011476",
"term": "autologous anti-mesothelin T-cell receptor fusion construct/PD-1:CD28 switch receptor-expressing T cells TC-510",
"field": "Oncology and biomedicine",
"definition": "A preparation of autologous T lymphocytes that have been genetically engineered to express a single-domain antibody that recognizes human tumor-associated antigen (TAA) mesothelin (MSLN), fused to the N-terminus of the CD3-epsilon T-cell receptor (TCR) subunit which, upon expression is incorporated into the endogenous TCR complex, and a PD-1:CD28 switch receptor composed of the extracellular ligand binding domain of the human inhibitory receptor programmed cell death protein 1 (PD-1; PDCD1) fused to the transmembrane and cytoplasmic co-stimulatory signaling domains of CD28, with potential immunomodulating and antineoplastic activities. Upon reintroduction into the patient, autologous anti-MSLN TCR fusion construct/PD-1:CD28 switch receptor-expressing T cells TC-510 specifically target and bind to MSLN-expressing tumor cells. This leads to T-cell activation and T-cell mediated lysis of MSLN-expressing tumor cells. The switch receptor expressed by the engineered T cells TC-510 targets and binds to the PD-1 ligands, programmed cell death ligand 1 (PD-L1) and 2 (PD-L2), expressed on tumor cells. The nature of the PD-1/CD28 switch receptor fusion protein prevents the normal PD1/PD-L1-mediated T-cell suppression and, instead, promotes signaling through the CD28 domain, which results in the stimulation of T-lymphocytes. This induces enhanced toxicity against tumor cells. Mesothelin, a cell surface glycoprotein involved in cell adhesion, is overexpressed in a variety of cancer cell types.",
"synonyms": [
"autologous anti-MSLN TCR fusion construct/PD-1:CD28 switch receptor-expressing T cells TC-510",
"autologous anti-mesothelin PD-1:CD28 switch receptor-expressing TRuC-T cells TC-510"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/autologous-anti-mesothelin-t-cell-receptor-fusion-construct-pd-1-cd28-switch-t/"
}
Record 2,808 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.